BRAF and pilocytic astrocytoma: In a study, 57% of seven pLGG patients (four patients with gangliomas, one patient each with xanthoastrocytoma, ganglio-neurocytoma and pilocytic astrocytoma; median age diagnosis of 75.2 months) with the BRAF V600E mutation responded to Vemurafenib, which was well-tolerated, with dermatological toxicity as the main adverse effect [83].